Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$21.11 USD
-0.47 (-2.16%)
Updated Apr 22, 2024 11:55 AM ET
After-Market: $21.83 +0.73 (3.44%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NTLA 21.11 -0.47(-2.16%)
Will NTLA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NTLA
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?
Other News for NTLA
First Week of June 21st Options Trading For Intellia Therapeutics (NTLA)
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Biotech Alert: Searches spiking for these stocks today
Intellia Therapeutics Welcomes New Principal Accounting Officer
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)